Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus

Pediatric Transplantation

Volumn 15, Issue 8, 2011, Pages 784-789

  Behnke Hall, Kachina ^a   Bauer, Juergen ^a   Thul, Josef ^a   Akintuerk, Hakan ^a   Reitz, Katharina ^a   Bauer, Anna ^a   Schranz, Dietmar ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

children; everolimus; heart transplantation; renal insufficiency

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; TACROLIMUS;

ABSCESS; ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY FUNCTION; MALE; OSTEOMYELITIS; PNEUMONIA; PRESCHOOL CHILD; SCHOOL CHILD; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

ADOLESCENT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG SUBSTITUTION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 82155196444     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01550.x     Document Type: Article

References (60)

1. Schowengerdt KO,. Advances in pediatric heart transplantation. Curr Opin Pediatr 2006: 18: 512-517. (Pubitemid 44401287)
2. Taylor DO, Stehlik J, Edwards LB, et al., Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009: 28: 1007-1022.
3. Kirk R, Edwards LB, Aurora P, et al., Registry of the international society for heart and lung transplantation: Twelfth official pediatric heart transplantation report-2009. J Heart Lung Transplant 2009: 28: 993-1006.
4. Bodziak KA, Hricik DE,. Conversion from calcineurin inhibitors to mTOR inhibitors. Curr Opin Organ Transplant 2007: 12: 351-356. (Pubitemid 47075670)
5. Knight RJ, Kahan BD,. The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006: 70: 994-999. (Pubitemid 44344067)
6. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481-508.
7. Pascual J,. Everolimus in clinical practice-Renal transplantation. Nephrol Dial Transplant 2006: 21 (Suppl 3): iii18-iii23. (Pubitemid 44018929)
8. Flechner SM, Goldfarb D, Solez K, et al., Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007: 83: 883-892. (Pubitemid 46682728)
9. Mehrabi A, Fonouni H, Kashfi A, et al., The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006: 20 (Suppl 17): 30-43. (Pubitemid 44697898)
10. Chueh SC, Kahan BD,. Clinical application of sirolimus in renal transplantation: An update. Transpl Int 2005: 18: 261-277. (Pubitemid 41726888)
11. Guerra G, Srinivas TR, Meier-Kriesche HU,. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007: 20: 813-827. (Pubitemid 47390195)
12. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA,. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006: 82: 1153-1162. (Pubitemid 44748017)
13. Kirchner GI, Meier-Wiedenbach I, Manns MP,. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004: 43: 83-95. (Pubitemid 38283132)
14. Mabasa VH, Ensom MH,. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 2005: 27: 666-676. (Pubitemid 41437646)
15. Kovarik JM, Noe A, Berthier S, et al., Clinical development of an everolimus pediatric formulation: Relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol 2003: 43: 141-147. (Pubitemid 36125940)
16. Rico J, Cruzado JM, Bestard O, et al., Subclinical rejection and sirolimus associated edema in renal allograft recipients. Transpl Int 2007: 20: 636-639. (Pubitemid 46872752)
17. Van Gelder T,. The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings. Neth J Med 2007: 65: 3-4.
18. Zuckermann A, Manito N, Epailly E, et al., Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008: 27: 141-149. (Pubitemid 351221042)
19. Vitko S, Wlodarczyk Z, Kyllonen L, et al., Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006: 6: 531-538. (Pubitemid 43382139)
20. Ettenger RB, Grimm EM,. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001: 38: S22-S28. (Pubitemid 32916886)
21. Vigano M, Tuzcu M, Benza R, et al., Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis. J Heart Lung Transplant 2007: 26: 584-592. (Pubitemid 46818043)
22. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J,. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777-786. (Pubitemid 32879845)
23. Flechner SM, Goldfarb D, Modlin C, et al., Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002: 74: 1070-1076. (Pubitemid 35216097)
24. Wali R, Pearson TC, Shidban H, Patel A, Chan L, Gordon RD,. SPARE-THE-NEPHRON (STN) TRIAL: Interim analysis of renal function after 12 months of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients. Transplantation 2006: 82 (Suppl. 3 WTC): 432.
25. Pearson TC, Wali R, Shidban H, Patel A, Chan L, Patel D,. SPARE-THE-NEPHRON (STN) TRIAL: One-year interim efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients. Transplantation 2006: 82 (Suppl. 3 WTC): 432.
26. Lorber MI, Ponticelli C, Whelchel J, et al., Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005: 19: 145-152. (Pubitemid 40424882)
27. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP,. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560-1567. (Pubitemid 36014229)
28. Gonzalez-Vilchez F, De Prada JA, Exposito V, et al., Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008: 27: 1135-1141.
29. Lehmkuhl H, Hetzer R,. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005: 24: S201-S205; discussion S10-1. (Pubitemid 40379799)
30. Lehmkuhl HB, Arizon J, Vigano M, et al., Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009: 88: 115-122.
31. Ross H, Pflugfelder P, Haddad H, et al., Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: A pilot study. Transpl Int 2010: 23: 31-37.
32. Gullestad L, Iversen M, Mortensen SA, et al., Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010: 89: 864-872.
33. Rothenburger M, Zuckermann A, Bara C, et al., Recommendations for the use of everolimus (Certican) in heart transplantation: Results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007: 26: 305-311. (Pubitemid 46498769)
34. Lehmkuhl H, Ross H, Eisen H, Valantine H,. Everolimus (certican) in heart transplantation: Optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005: 37: 4145-4149. (Pubitemid 43015978)
35. Hummel M,. Recommendations for use of Certican (everolimus) after heart transplantation: Results from a German and Austrian Consensus Conference. J Heart Lung Transplant 2005: 24: S196-S200; discussion S10-1. (Pubitemid 40379798)
36. Pape L, Ahlenstiel T, Ehrich JH, Offner G,. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007: 11: 291-295. (Pubitemid 46570146)
37. Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E,. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010: 14: 402-408.
38. Schubert S, Lehmkuhl H, Huebler M, Hetzer R, Berger F,. Comparison of de novo everolimus, AZA and MMF in ciclosporine based immunosuppressive protocol in pediatric heart transplant recipients. J Heart Lung Transplant 2010: 29: S107.
39. Schwartz GJ, Munoz A, Schneider MF, et al., New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009: 20: 629-637.
40. Bharat W, Manlhiot C, Mccrindle BW, Pollock-Barziv S, Dipchand AI,. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr Transplant 2009: 13: 111-118.
41. Navarro-Manchon J, Martinez-Dolz L, Almenar Bonet L, et al., Predictors of renal dysfunction at 1 year in heart transplant patients. Transplantation 2010: 89: 977-982.
42. Kamphues C, Bova R, Rocken C, et al., Safety of mycophenolate mofetil monotherapy in patients after liver transplantation. Ann Transplant 2009: 14: 40-46.
43. Lindenfeld J, Miller GG, Shakar SF, et al., Drug therapy in the heart transplant recipient: Part II: Immunosuppressive drugs. Circulation 2004: 110: 3858-3865. (Pubitemid 40023985)
44. Filler G, Sharma AP,. High prevalence of chronic kidney disease in pediatric solid organ transplantation. Pediatr Transplant 2009: 13: 7-10.
45. Andersen TB, Eskild-Jensen A, Frokiaer J, Brochner-Mortensen J,. Measuring glomerular filtration rate in children; can cystatin C replace established methods? A review. Pediatr Nephrol 2009: 24: 929-941.
46. Aufricht C, Balbisi A, Gerdov C, Muller T, Lothaller MA, Balzar E,. Formula creatinine clearance as a substitute for 24-hour creatine clearance in children with kidney transplantation. Klin Padiatr 1995: 207: 59-62.
47. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A,. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 58: 259-263.
48. Benden C, Kansra S, Ridout DA, et al., Chronic kidney disease in children following lung and heart-lung transplantation. Pediatr Transplant 2009: 13: 104-110.
49. Groetzner J, Kaczmarek I, Schulz U, et al., Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009: 87: 726-733.
50. Saurina A, Campistol JM, Piera C, et al., Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006: 21: 488-493. (Pubitemid 43160007)
51. Garcia CD, Bittencourt VB, Alves AB, et al., Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 2006: 38: 1901-1903. (Pubitemid 44190076)
52. Costello JM, Pahl E,. Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients. Paediatr Drugs 2002: 4: 705-715. (Pubitemid 35316390)
53. Chin C, Naftel DC, Singh TP, et al., Risk factors for recurrent rejection in pediatric heart transplantation: A multicenter experience. J Heart Lung Transplant 2004: 23: 178-185. (Pubitemid 38175295)
54. Stewart S, Winters GL, Fishbein MC, et al., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005: 24: 1710-1720. (Pubitemid 41641841)
55. Kushwaha SS, Khalpey Z, Frantz RP, et al., Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005: 24: 2129-2136. (Pubitemid 41814736)
56. Lehmkuhl HB, Mai D, Dandel M, et al., Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007: 26: 700-704. (Pubitemid 47007710)
57. Ettenger R, Hoyer PF, Grimm P, et al., Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 2008: 12: 456-463. (Pubitemid 351652075)
58. Falger JC, Mueller T, Arbeiter K, et al., Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 565-569.
59. Hymes LC, Warshaw BL,. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005: 9: 520-522. (Pubitemid 41153274)
60. Hoyer PF, Ettenger R, Kovarik JM, et al., Everolimus in pediatric de nova renal transplant patients. Transplantation 2003: 75: 2082-2085. (Pubitemid 36793297)